[Lipoprotein(a) and the cardiovascular risk during estrogen-progestin replacement therapy in postmenopause].
A homogeneous group of 37 patients, aged between 52 and 61 years was considered in relationship to the metabolic response during hormonal replacement therapy (HRT). A free endocrinological-metabolic pathology control group, formed by 40 patients, who were not treated with any therapy, was also considered. Study-trial was comprehensive of a 123 months follow-up, with some periods of study at 0, +6, +12 months. Metabolic responses of lipoprotein(a) and apolipoprotein A and B during the different follow-up steps were determined. Total and fractioned cholesterol and triglycerides were also determined. Significant correlations were shown between Lipo(a) and Apo B and also between Lipo(a) and LDL in both groups considered Lipoprotein(a) was determined by ELISA methodic and turbidimetric methodic. The aim of our study was to verify the importance of the new markers of the atheromatous risk. The reduction of lipoproteins middle value observed in the HRT group shows a little, but however present, estrogens action to the Lipo(a) itself. This fact testifies to the benefit of the use of HRT in post-menopause also as reg ards an evaluated cardiovascular risk inhibition.
Porcelli
A
A
Cattedra di Clinica Ostetrica e Ginecologica, Facoltà di Medicina e Chirurgia--Novara, Università degli Studi, Torino.
Calleri
L
L
Gallello
D
D
Taccani
C
C
Surico
N
N
D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology*; D015914:Estrogen Replacement Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008875:Middle Aged; D045167:Progesterone Congeners / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors
D001054:Apolipoproteins A; D001055:Apolipoproteins B; D015415:Biomarkers; D017270:Lipoprotein(a); D045167:Progesterone Congeners
Lipoproteina(a) e rischio cardiovascolare in corso di terapia estroprogestinica sostitutiva nella postmenopausa.